ts; 3) a follow-up of patients who were previously enrolled in the Phase I, I I, and III (EPIC) studies to better understand the long-term safety of Idusig; and 4) In the second half of 2014, a trial will be initiated to assess the long-term safety of Iclusig treatment, including the long-term risk of v